Severe Asthma Clinical Trial
Official title:
National Survey on Care Pathway and Quality of Life in Patients With Severe Asthma According to Their Phenotype.
The SECOND SOUFFLE survey focuses on aspects of care and quality of life in a period when the landscape of severe asthma is changing in the context of biotherapies. Moreover survey on care pathway and quality of life of the asthmatic severe population according to their phenotype have never been done. It is likely to bring results in a relatively fast time, results that can lead to guide the criteria collected in RAMSES a national severe asthma cohort and future research tracks of this cohort.
The Th2 phenotype corresponds to severe asthmatic patients eligible for new subcutaneous targeted asthma therapies, which can bring about a real improvement in symptoms and quality of life. No data are available on the proportion of this patient population since the advent of biotherapies, as well as the impact on quality of life and pathway by phenotype. The survey will be conducted using a collection of data on a dedicated questionnaire including validated questionnaires on the quality of life and the control of the asthmatic disease as well as the therapeutic observance. The objectives of the survey are to estimate the phenotypic profile distribution of severe asthmatic patients and the proportion currently treated by biotherapies as well as the impact of the pathology on the clinical profile and quality of life of patients with severe asthma. Investigative pulmonologists selected from university or general hospitals or from private practice will propose to their eligible patients to participate in the study. Patients informed and not opposed to participating will complete, at the end of the consultation, the dedicated questionnaire pre-filled by the pulmonologist (for the medical data required for phenotypic stratification). The questionnaires will be collected from the centers and the data centralized to establish the database. Analyzes will be done in order to stratify the populations according to their phenotype and to analyze the data globally and by subgroup. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05018299 -
Evaluate the Efficacy and Safety of FB704A in Adult With Severe Asthma
|
Phase 2 | |
Recruiting |
NCT05472324 -
Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma.
|
Phase 2 | |
Recruiting |
NCT04914078 -
Severe Asthma Exacerbations and Mepolizumab Treatment
|
||
Completed |
NCT05576454 -
Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects
|
Phase 1 | |
Recruiting |
NCT04520165 -
Effect of Biologicals on Alternative Functions of Eosinophils in Severe Asthma
|
||
Not yet recruiting |
NCT04463836 -
Phenotyping Circulating and Lung Resident Eosinophils in Severe Asthma (P-CLESA)
|
||
Enrolling by invitation |
NCT06421402 -
K-HEALTH in AIR - Barcelona Pilot - Cohort
|
||
Recruiting |
NCT03377920 -
Predictive Value of Spirometric PIF to Produce PIF Rate Needed for the Use of Current DPI's.
|
N/A | |
Recruiting |
NCT04565483 -
Predictive Signature of Benralizumab Response
|
Phase 4 | |
Recruiting |
NCT04045587 -
International Severe Asthma Registry: Canadian Cohort
|
||
Completed |
NCT05616338 -
Modeling Bronchial Epithelium in Severe Asthma With Human Induced Pluripotent Stem Cells (iPSC)
|
N/A | |
Active, not recruiting |
NCT02038374 -
Clinico-biological Correlation of Severe Asthma in Children
|
N/A | |
Active, not recruiting |
NCT02114034 -
Cohort Analysis of Clinical and Biological Severe Childhood Asthma
|
||
Recruiting |
NCT06035289 -
Register Schweres Asthma - German Asthma Net e.V.
|
||
Not yet recruiting |
NCT03532685 -
Clinical, Inflammatory and Functional Evaluation of a Population of Severe and Obese Asthmatics: Follow up
|
N/A | |
Completed |
NCT03931954 -
Prevalence of the Eosinophilic Phenotype Among Severe Asthma Patients
|
||
Recruiting |
NCT03984253 -
Swiss Severe Asthma Register
|
||
Recruiting |
NCT03435237 -
Phenotyping Asthma for Bronchial Thermoplasty
|
||
Recruiting |
NCT03476109 -
Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma.
|
Phase 4 | |
Active, not recruiting |
NCT06389058 -
Using NLP and Neural Networks to Autonomously Identify Severe Asthma and Determine Study Eligibility in a Large Healthcare System
|